NDT Advance Access published online on July 20, 2006
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl340
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Germany
* To whom correspondence should be addressed. Background. Everolimus is a potent immunosupressant used in renal transplant therapy, but its effects on renal endothelial cell regeneration after injury are unknown. The effects of an everolimus therapy were investigated in a model of renal thrombotic microangiopathy (TMA) with specific endothelial cell (EC) injury in the rat in vivo as well as in glomerular ECs in vitro. Methods. During the early regenerative phase (day 3) of the renal microvascular injury model in vivo, everolimus inhibited glomerular EC proliferation by up to 60% compared with vehicle-treated rats, whereas apoptosis was not different in these groups. This decreased EC proliferation was associated with an enhanced deposition of fibrin in everolimus treated animals on day 3. In cultured glomerular endothelial cells, everolimus effectively and dose dependently inhibited cellular proliferation. This anti-proliferative effect was associated with a reduced phosphorylation of the p70S6 kinase and reduction of the pro-angiogenic factor VEGF in glomeruli in vivo and in cultured podocytes in vitro. Results. Despite the prolonged EC repair and in contrast to the anti-Thy1 nephritis model, everolimus therapy did not disturb the long-term repair reaction in this thrombotic microangiopathy model. Conclusion. Everolimus is anti-proliferative for glomerular EC in vitro and in vivo and does not seem to have detrimental long-term effects in experimental renal TMA, when only the glomerular endothelium, but not the mesangium is severely injured. The authors wish it to be known that, in their opinion, the first two authors contributed equally to this work.
Received October 21, 2005
Accepted May 17, 2006
Original Article
Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy
Katja Keller 1, Christoph Daniel 1, Harald Schöcklmann 2, Karl-Hans Endlich 3, Dontscho Kerjaschki 4, Richard J. Johnson 5, and Christian Hugo 1 *
2 Department of Nephrology and Hypertension, University of Schleswig-Holstein, Campus Kiel, Germany
3 Institute of Anatomy, University of Greifswald, Germany
4 Institute for Clinical Pathology, University of Vienna, Austria
5 Division of Nephrology Hypertension and Renal Transplantation, University of Florida, Gainesville, USA
Christian Hugo, E-mail: christian.hugo{at}rzmail.uni-erlangen.de
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Daniel, A. Wagner, B. Hohenstein, and C. Hugo Thrombospondin-2 therapy ameliorates experimental glomerulonephritis via inhibition of cell proliferation, inflammation, and TGF-{beta} activation Am J Physiol Renal Physiol, November 1, 2009; 297(5): F1299 - F1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Letavernier, P. Bruneval, S. Vandermeersch, J. Perez, C. Mandet, M.-F. Belair, J.-p. Haymann, C. Legendre, and L. Baud Sirolimus interacts with pathways essential for podocyte integrity Nephrol. Dial. Transplant., February 1, 2009; 24(2): 630 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-Z. Liu, J. Z. Zheng, X.-R. Wang, and B.-H. Jiang Endothelial p70 S6 Kinase 1 in Regulating Tumor Angiogenesis Cancer Res., October 1, 2008; 68(19): 8183 - 8188. [Abstract] [Full Text] [PDF]
|
|